Endocan plays a role in tumour angiogenesis and tumour growth. The aim of this study was to detect the expression of endocan in hepatocellular carcinoma (HCC) tumour-associated endothelial cells and to correlate endocan expression with clinicopathological parameters and tumour angiogenesis. Tumour tissues and surrounding noncancerous hepatic parenchyma from 42 primary HCC patients were studied. Endothelial cells were isolated using magnetic microbeads conjugated with anti-CD31 and endocan expression was evaluated by real-time reverse transcription-polymerase chain reaction, Western blotting and immuno histochemistry. Endocan was significantly over-expressed in endothelial cells isolated from HCC tumours compared with corresponding non-cancerous liver tissues. In addition, the endocan mRNA level was significantly correlated with the serum a-fetoprotein level, intra-tumoural microvessel density, vascular endothelial growth factor mRNA, and vascular and venous invasion. The over-expression of endocan in tumour endothelial cells was closely related to the process of angiogenesis and pathogenesis in HCC, and suggests that endocan might be a useful marker for HCC progression.
Introduction
With over half a million new cases each year, hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related death. 1 It is particularly prevalent in Asia and subSaharan Africa, but there has also been a rising incidence and a progressive increase in HCC-related mortality in the USA and western Europe. 2, 3 In China, HCC ranks as the second leading cause of cancer-related death. 4 HCC is characterized by early invasion into blood vessels as well as intrahepatic metastasis. 5 Despite advances in surgical and non-surgical therapies, the mortality and outcome of HCC remains poor *L-Y Chen and X Liu contributed equally to this work.
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and unchanged. It is, therefore, critical to understand the molecular mechanism of this highly aggressive cancer and to develop novel therapies for it.
Anti-angiogenesis is a promising therapeutic strategy for cancer treatment. Tumour angiogenesis plays an important role in HCC, in the primary tumour, during the progression and recurrence stages, and during metastasis, the latter being a predictor for poor prognosis in patients. 6 Angiogenesis in HCC and other solid tumours is based on the same fundamental principles of activation, proliferation and migration of endothelial cells. 7 -9 As the activated tumour endothelial cells play a central role in the whole process of angiogenesis, they can serve as targets in anti-angiogenic studies. Endothelial cells are heterogeneous in different organs, tissues and tumours, and distinct molecules on endothelial cells need to be investigated as therapeutic targets. 10 Endocan, previously known as endothelial cell-specific molecule-1, was originally cloned from a human endothelial cell cDNA library in 1996. 11 As a novel soluble dermatan sulphate proteoglycan secreted by cultured endothelial cells, endocan is primarily expressed in endothelial cells of the kidney, lung and the gastrointestinal tract of humans; it plays an important role in vascular cell biology and human lung physiology. 11, 12 A recent cDNA microarray study, carried out to compare alterations in gene expression in highly aggressive versus less aggressive melanoma cells, showed a 44-fold increase in endocan mRNA levels in the highly aggressive melanoma cells. 13 High endocan mRNA levels have been correlated with poor prognosis and metastasis in several types of cancers, including breast, renal and lung cancer, and have been correlated with other associated markers. 14 -17 There is a strong correlation between the expression of endocan and the angiogenic marker vascular endothelial growth factor (VEGF) and the degree of tumour vascularity. 12, 18 Although endocan plays an important role in tumour angiogenesis and tumour growth, there is no information on the role of endocan in HCC endothelial cells.
In the present study, endothelial cells from freshly resected specimens of HCC and corresponding surrounding non-cancerous liver tissue were immunopurified to investigate the expression of endocan in HCC endothelial cells. 
Patients and methods

PATIENTS AND SAMPLES
IMMUNOMAGNETIC ISOLATION AND PURIFICATION OF ENDOTHELIAL CELLS
The isolation and culture of endothelial cells was carried out as reported previously with minor modifications. 19, 20 To remove blood, freshly collected tissues were washed Endocan gene over-expression in hepatocellular carcinoma thoroughly in cold 0.01 mM phosphatebuffered saline (PBS) solution, pH 7.4, containing 100 mg/ml streptomycin and 30 mg/ml penicillin. Tissue was then minced finely into small fragments (1 × 1 mm 3 ), and then digested with 0.1% collagenase A, 0.2% elastase and 1 U/µl DNase 1 (Gibco ® Cell Culture, Carlsbad, CA, USA ) at 37°C for 90 min to yield a single-cell suspension, which was then passed through a nylon sieve with a pore size of 75 µm. The fragments retained by the sieve were washed three times with 0.01 mM PBS at 600 g for 5 min. The tissue pellet was dissociated into a single cell suspension by incubation in pre-warmed 0.1% collagenase type IV solution (Gibco ® Cell Culture) in Dulbecco's modified Eagle ' s medium (DMEM; Gibco ® Cell Culture). After 30 min of digestion at 37°C in a shaking water bath, the reaction was stopped with 10% fetal calf serum (Gibco ® Cell Culture).
The tissues and cells were resuspended and washed three times with DMEM, then the pellet was passed through a nylon mesh (pore size 55 µm) and the single cell suspension was washed with 0.01 mM PBS at least three times. Magnetic beads (Dynabeads ® M-450; Dynal Biotech, Oslo, Norway), coated with purified monoclonal antibody to CD31/platelet-endothelial cell adhesion molecule-1, were added and incubated with the single cell suspensions for 20 min at 4°C. The cell suspensions were then separated in a magnetic particle concentrator (Dynal Biotech). The purified cells were then incubated at 37°C in a humidified atmosphere of 5% CO 2 with 10% DMEM, with a change in the medium every 2 days. Cells were passaged with 0.025% trypsin and 0.01% ethylenediaminetetraacetic acid (Sigma-Aldrich, St Louis, MO, USA) in sterile 0.01 mM PBS, and an aliquot of cells was counted in a haemocytometer. Cell viability was assessed by trypan blue exclusion. The remaining cells were pelleted, snap frozen in liquid nitrogen and stored at -80°C until further use. Immunostaining with von Willebrand factor and flow cytometry analysis were used to confirm the purity of the endothelial cells as described previously. 21 
RNA EXTRACTION AND cDNA SYNTHESIS
Total RNA was isolated from the endothelial cells using TRIzol ® reagent (Invitrogen™, Carlsbad, CA, USA). The optical density of RNA at A 260/280 nm was 1.6 -2.0. The integrity of RNA was confirmed by the presence of intact 18S and 28S bands after electrophoresis on a 1% agarose gel. The first-strand cDNA synthesis reaction was performed with a reverse transcription kit (MBI Fermentas, Vilnius, Lithuania) according to the manufacturer ' s instructions, initially at 42°C for 60 min and then at 70°C for 10 min.
REAL-TIME QUANTITATIVE RT-PCR
Real-time quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) was carried out to evaluate the levels of endocan and VEGF mRNA. The primer sequences for real-time quantitative RT-PCR analysis were as follows: endocan -forward primer 5′-CA GGCATGGATGGCATGAAG-3′, and reverse primer 5′-CTGACTGGCAGTTGCAGGTCTC-3′; VEGF -forward primer 5′-CAGCACGA GCTACCTCAGCAAG-3′, and reverse primer 5′-TTTAGACATGCATCGGCAGGAA-3′; β-actin -forward primer 5′-AATGCTTCTAGGCGGA CTATGA-3′, and reverse primer 5′-CAAGAA AGGGTGTAACGCAACT-3′. For quantification of the level of expression of the endocan and VEGF genes, the Quantitative SYBR ® Green RT-PCR Kit (Applied Biosystems, Foster City, CA, USA) was used on an ABI Prism ® 7000 Sequence Detection System (Applied Biosystems) according to the manufacturer's instruction using the following parameters: Endocan gene over-expression in hepatocellular carcinoma one cycle of denaturation at 95°C for 5 min, then 30 cycles of denaturation at 94°C for 30 s, annealing/extension at 60°C for 45 s, followed by a final 30 s extension period at 72°C. Each quantitative RT-PCR reaction was repeated at least three times and all PCR assays were performed in a 25 µl final volume. The amount of mRNA in each sample was automatically quantitated using ABI 7000 software (Applied Biosystems). The expression of β-actin was quantified and used as an internal control, to standardize the amount of RNA.
WESTERN BLOT ANALYSIS
Cells were lysed in 10 µl cold RIPA buffer (0.15 M NaCl, 1% NP40, 0.01 M deoxycholate, 0.1% sodium dodecyl sulphate [SDS], 0.05 M Tris-HCl [pH 8.0], 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, and 10 µg/ml each of aprotinin, pepstatin and leupeptin). Total cell lysates were transferred to a 1.5 ml tube on ice and then centrifuged (400 g, 20 min) at 4°C. The protein concentration was determined with a bicinchoninic acid (BCA) protein assay kit (Biocolor Biotech, Shanghai, China). Proteins were suspended in loading buffer, heated at 100 ºC for 5 min to denature them, then separated by SDS polyacrylamide gel electrophoresis using a 10% polyacrylamide gel and electrophoretically transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA) at 40 V for 105 min. The membrane was blocked with 5% non-fat milk powder for 2 h, washed with Trisbuffered saline with Tween ® 20 (TBS-T: 20 mM Tris-HCl, 137 mM NaCl, 1.5% non-fat dried milk and 0.1% Tween ® 20, pH 7.6) and incubated with mouse anti-endocan antibody (dilution 1:1000; R&D Systems, Minneapolis, MN, USA) overnight at 4°C. Membranes were then washed three times in 20 mM TBS-T to remove the primary antibody, followed by incubation with an antimouse horseradish peroxidaseconjugated secondary antibody (1:200 dilution; Dako, Glostrup, Denmark) at room temperature for 1 h. Membranes were then washed a final three times in 20 mM TBS-T to remove the secondary antibody, and the protein bands were visualized by SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford, IL, USA) and exposed with Kodak X-ray film (Kodak, Rochester, NY, USA). The membrane was reblotted with anti-β-actin antibodies (Zymed ® , San Francisco, CA, USA) diluted 1:10000 as an internal control.
IMMUNOHISTOCHEMICAL STAINING AND MVD MEASUREMENT
For immunohistochemical analysis, 4 µm sections of HCC tumour tissue were cut from paraffin blocks and baked at 50 -60°C for at least 2 h. The paraffin sections were dewaxed with xylene and rehydrated through a graded alcohol series. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 30 min. For antigen retrieval, tissue sections were pre-treated in 0.01 mM, citrate buffer, pH 6.0, using a water bath for 15 min. Goat serum (1%) was applied to the sections for 1 h at room temperature to prevent nonspecific binding. Primary antibody was applied for 2 h at 37°C or overnight at 4°C in a humidified chamber: mouse antiendocan (R&D Systems,) diluted 1:100, and mouse anti-CD34 (Santa Cruz Biotechnology Santa Cruz, CA, USA) diluted 1:50. For negative controls, primary antibody was replaced with 0.02 mM PBS, pH 7.6. Slides were then washed three times in 0.02 mM PBS to remove the primary antibody and an anti-mouse secondary antibody kit (Jing Mei Biotech, Shanghai, Endocan gene over-expression in hepatocellular carcinoma China) was applied according to the manufacturer's instruction. Slides were then washed a final three times in 0.02 mM PBS to remove the secondary antibody and a peroxidase/diamino benzidine reaction was performed to visualize the protein staining. Histomorpho metric analysis was carried out by the Image-Pro Plus image analysis system (Media Cybernetics Inc., Bethesda, MD, USA).
To determine microvessel density (MVD), the four most vascularized areas of the tumours were identified under a low-power light microscope (× 100). The number of microvessels were counted in five high-power fields (× 200) in each area and the mean overall count was calculated. Samples were counted independently by two pathologists at different times. Any brown-stained endothelial cell cluster distinct from adjacent microvessels, tumour cells, or other stromal cells was considered as a single countable microvessel. The grading results were further verified using the automated Chromavision Cellular Imaging System (Chromavision Medical Systems, San Juan Capistrano, CA, USA).
STATISTICAL ANALYSIS
The mean ± SD of the data were calculated and then analysed using the SPSS ® statistical package, version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . An unpaired Student's ttest was used to analyse the difference in endocan mRNA and protein levels in tumour and non-cancerous tissues. To analyse the correlation of endocan mRNA levels and clinicopathological parameters, MannWhitney U-tests and Kruskal-Wallis tests were used. The correlation between endocan mRNA levels and MVD and VEGF mRNA levels were analysed using Pearson's exact test. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS AND SAMPLES
Tumour tissue and surrounding noncancerous hepatic parenchyma were collected from 42 primary HCC patients (38 males, four females; mean age 54.5 years, range 32 -74 years). The demographic and clinical data for the HCC patients are summarized in Table 1 .
ENDOTHELIAL CELL ISOLATION AND PURITY CONFIRMATION
All samples were subjected to immunoselection and 1 -5 × 10 7 positively isolated cells were obtained from every sample. The purity of all endothelial cell samples was tested using the endothelial cell marker von Willebrand factor (Fig. 1) . Flow cytometry revealed that the immunopurification technique yielded endothelial cell purity of > 95% in all samples. Thus, the isolation technique resulted in a highly pure population of endothelial cells for subsequent analyses.
MRNA EXPRESSION OF ENDOCAN IN HCC ENDOTHELIAL CELLS
Real-time quantitative RT-PCR conducted on HCC tumour samples and corresponding non-cancerous hepatic tissues showed that endocan mRNA was noticeably up-regulated in most tumour tissues compared with normal controls (Fig. 2) . In contrast, the noncancerous liver tissues showed low levels of endocan mRNA. The endocan/β-actin mRNA level in HCCs was significantly higher than that in non-cancerous livers (mean ± SD 0.521 ± 0.152 versus 0.064 ± 0.018, P < 0.001; Fig. 2 ).
CORRELATION BETWEEN ENDOCAN MRNA AND CLINICAL PARAMETERS
The correlation between endocan mRNA levels in the 42 cases of HCC and corresponding non-cancerous hepatic tissues were Endocan gene over-expression in hepatocellular carcinoma statistically analysed. There was a significant correlation between high levels of endocan mRNA and high (≥ 20 ng/ml) serum AFP levels (P = 0.002). Endocan over-expression was significantly higher in HCC patients with vascular (P = 0.004) and venous invasion (P = 0.001). There was also a significant correlation of high endocan mRNA levels with liver cirrhosis (P = 0.025), but no significant relationship between endocan mRNA and age, gender, tumour size, multiplicity, HBV infection or tumour differentiation. 
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ENDOCAN PROTEIN LEVELS IN HCC ENDOTHELIAL CELLS
Endocan protein was up-regulated in endothelial cells from HCC tissue, in contrast to a low level of protein observed in noncancerous hepatic tissues (Fig. 3) .
Immunohistochemical staining with a mouse anti-endocan antibody demonstrated that endocan protein was elevated in HCC tissues, was present in 57.27% of the HCC specimens and was localized mainly in the tumour endothelial cells (Fig. 4) . 
MVD, AND VEGF AND ENDOCAN MRNA LEVELS IN HCC PATIENTS
Specific staining of microvessels using anti-CD34 antibodies was evaluated. The mean ± SD MVD in HCC was 66.7 ± 11.2 vessels/mm 3 compared with 11.6 ± 5.2 vessels/mm 3 in non-cancerous liver tissues. A significant positive correlation between the level of endocan mRNA and MVD was observed (r = 0.74, P < 0.001). The expression of VEGF, known to play a vital role in the angiogenesis and invasion of HCC, was also examined in this study and a high positive correlation between endocan mRNA and VEGF mRNA levels was noted (r = 0.55, P < 0.0001). A significant positive correlation 
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was also found between the level of VEGF mRNA levels and MVD (r = 0.47, P < 0.002) (Fig. 5 ).
Discussion
Tumour angiogenesis plays an important role in HCC progression and recurrence, both of which are usually predictors for poor prognosis. 6, 22 As the main target of angiogenesis treatment, tumour endothelial cells present specific markers that potentially promise a molecular basis for vessel-targeted therapy. Although a variety of biological markers have been investigated, most are unsuitable.
Endothelial cells represent a minor fraction of the cell population that is enmeshed in tumour tissue, and the difficulty of isolating and purifying endothelial cells has limited their study. 9 In the present study, endothelial cells were isolated from HCC tumour tissues using magnetic microbeads conjugated with anti-CD31 antibody, which effectively avoids contamination and retains the purity of the endothelial cells. Having verified that endothelial cells had been purified, significantly high levels of endocan mRNA and protein were then demonstrated in the endothelial cells of HCC tissue but not in the surrounding non-cancerous cells. A correlation was also found between endocan mRNA levels and MVD, as well as with VEGF mRNA levels in HCC tissue.
Endocan is a novel molecule and is a key player in the regulation of major processes, such as cell adhesion, and in inflammatory disorders and tumour progression. 23 A previous study has indicated that endocan is associated with cancers including HCC and is mainly located in endothelial cells. 24 In the present study, it was shown that endocan mRNA was significantly over-expressed in HCC endothelial cells compared with endothelial cells from non-cancerous neighbouring liver tissues.
The correlation between endocan expression and clinicopathological parameters was also investigated. The data suggested that endocan mRNA levels were not only associated with serum AFP levels, but also with vascular and venous invasion. Serum AFP was previously taken as a predictor of post-surgical recurrence of hepatocellular carcinoma, 25 and vascular and venous invasion indicate an invasive phenotype in HCC. 26 For patients with liver cirrhosis, the level of endocan expression tends to be higher than in those without cirrhosis. Cirrhosis is both a risk factor and a confounding factor for HCC, and the higher rate of survival of those with HCC and a liver without cirrhosis compared with those with a cirrhotic liver has been well documented. 27, 28 This suggests that the over-expression of endocan might also be correlated with the underlying mechanism of HCC and might, therefore, be a useful predictor for this disease.
It appears that VEGF may be the most important angiogenic factor in HCC known to date. 29 In the present study, it was found that the VEGF gene was over-expressed in the HCC samples studied and that it also correlated with endocan expression. A highly significant positive association between endocan mRNA levels and intra-tumoural MVD was also observed.
Endocan has been reported to be preferentially expressed in tumour endothelium and the treatment of cultured endothelial cells with VEGF has resulted in a dose-and time-dependent increase in endocan mRNA. 30 In the present study, it was confirmed using immunohistochemistry that endothelial cells showed immunoreactivity for endocan. These results suggest that endocan might be involved in tumour angiogenesis and be stimulated by angiogenic factors and, in this way, enhance tumour growth and progression. High levels of serum endocan have been reported to be directly correlated with tumour size in lung cancer. 31, 32 This putative role of endocan is further endorsed as anti-endocan antibodies prevent or slow down the growth of endocanexpressing xenografts in severe combined immunodeficient mice, without any direct in vitro antiproliferative effect. 32 Endocan is over-expressed during in vitro angiogenesis, but antisense knockout of endocan does not prevent this process. 33, 34 In addition, endocan is not involved in fibroblast growth factor-2-induced endothelial cell proliferation as it is not inhibited by anti-endocan antibodies. Thus, the cellular target of endocan seems to be the malignant epithelial cell rather than the endothelium itself. It could be speculated that endocan acts locally in a paracrine positive-feedback loop and could be an important player in supporting tumour growth which, in turn, acts by amplifying the effect of pro-tumoural growth factors 35 and by inhibiting effective immune cell migration into the tumour. 36 Endocan was not expressed in the normal liver in the present study. This was in agreement with a previous study, 30 and similar results have been obtained in renal carcinoma and endometrial cancer. 18, 21 Endocan has long been taken as an invading endothelial cell-specific molecule of largely unknown function. Further studies are needed to clarify the underlying mechanism of the cellular origin, generation, regulation and function of endocan in HCC tumoural endothelial cells.
In conclusion, the present study has provided the first evidence for the clinical relevance and function of endocan in HCC endothelial cells, primarily that endocan expression in tumour endothelial tissue is a marker of vascular invasion and could be implicated in the progression of HCC. Thus, unravelling treatment strategies involving the functional abrogation of endocan might provide new therapeutic approaches in the treatment of HCC.
